Top

Osteoporosis International

Published in:

01-02-2010 | Original Article

Peroxisome proliferator-activated receptor gamma polymorphism is related to peak bone mass: the JPOS study

Authors: J. Tamaki, M. Iki, A. Morita, Y. Ikeda, Y. Sato, E. Kajita, S. Kagamimori, Y. Kagawa, H. Yoneshima

Published in: Osteoporosis International | Issue 2/2010

Abstract

Summary

We analyzed 1,217 women to examine the effect of peroxisome proliferator-activated receptors gamma (PPARγ) C161 → T on bone status. Among 664 premenopausal women, the C161 → T is associated with low bone mineral density (BMD) at the total hip and femoral neck. Moreover, the odds ratio for osteopenia or osteoporosis at the femoral neck was 1.98 for premenopausal CT/TT genotypes.

Introduction

The impact of PPARγ on BMD has not been conclusively established. We examined if PPARγ C161T polymorphism is associated with BMD and its change.

Methods

We conducted a baseline survey in 1996 and a 10-year follow-up survey, Japanese Population-based Osteoporosis Study, with a sample population representative of Japanese women. Of these, 1,217 participants in the 1996 survey were analyzed cross-sectionally, while longitudinal analysis was performed on 563 women. A P value < 0.0042 (=0.05/12 for three menstrual statuses and four skeletal sites) was considered statistically significant after Bonferroni correction in multiple testing for cross-sectional analysis.

Results

The total hip and femoral neck BMDs were significantly higher for CC genotype than for CT/TT genotypes among 664 premenopausal women (P = 0.0020, P = 0.0022, respectively). Compared to the CC genotype, the odds ratio for osteopenia or osteoporosis (T-scores below −1) at the femoral neck was 1.98 for premenopausal CT/TT genotypes with statistical significance (P = 0.0041). Change of BMD at either skeletal site during the follow-up period was not significantly different for either menstrual status.

Conclusions

We conclude that the PPARγ C161T is associated with low peak bone mass.

Pocock NA, Eisman JA, Hopper JL et al (1987) Genetic determinants of bone mass in adults. A twin study. J Clin Invest 1987(80):706–710CrossRef

Huang QY, Li GH, Cheung WM et al (2007) Prediction of osteoporosis candidate genes by computational disease-gene identification strategy. J Hum Genet 53:644–655CrossRef

Greene ME, Blumberg B, McBride OW et al (1995) Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr 4:281–299PubMed

Hsueh WA, Law R (2003) The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease. Am J Cardiol 92:3J–9JCrossRefPubMed

Heikkinen S, Auwerx J, Argmann CA (2007) PPAR gamma in human and mouse physiology. Biochim Biophys Acta 1771:999–1013PubMed

Giaginis C, Tsantili-Kakoulidou A, Theocharis S (2007) Peroxisome proliferators -activated receptors (PPARs) in the control of bone metabolism. Fundam Clin Pharmacol 21:231–244CrossRefPubMed

Schwartz AV, Sellmeyer DE, Vittinghoff E et al (2006) Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349–3354CrossRefPubMed

Suzawa M, Takada I, Yanagisawa J et al (2003) Cytokines suppress adipogenesis and PPAR-gamma function through the TAK1/TAB1/NIK cascade. Nat Cell Biol 5:224–230CrossRefPubMed

Mbalaviele G, Abu-Amer Y, Meng A et al (2000) Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation. J Biol Chem 275:14388–14393CrossRefPubMed

10.

Hounoki H, Sugiyama E, Mohamed SG et al (2008) Activation of peroxisome proliferator-activated receptor gamma inhibits TNF-alpha-mediated osteoclast differentiation in human peripheral monocytes in part via suppression of monocyte chemoattractant protein-1 expression. Bone 42:765–774CrossRefPubMed

11.

Kudo O, Fujikawa Y, Itonaga I et al (2002) Proinflammatory cytokine (TNFa/IL-1a) induction of human osteoclast formation. J Pathol 198:220–227CrossRefPubMed

12.

Kwak HB, Jin HM, Ha H et al (2005) Tumor necrosis factor-α induces differentiation of human peripheral blood mononuclear cells into osteoclasts through the induction of p21(WAF1/Cip1). Biochem Biophys Res Commun 330:1080–1086CrossRefPubMed

13.

Rhee EJ, Oh KW, Lee WY et al (2005) The effects of C161→T polymorphisms in exon 6 of peroxisome proliferator-activated receptor-gamma gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women. Am J Obstet Gynecol 192:1087–1093CrossRefPubMed

14.

Tsuda E, Goto M, Mochizuki S et al (1997) Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234:137–142CrossRefPubMed

15.

Bucay N, Sarosi I, Dunstan CR et al (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260–1268CrossRefPubMed

16.

Samelson EJ, Broe KE, Demissie S et al (2008) Increased plasma osteoprotegerin concentrations are associated with indices of bone strength of the hip. J Clin Endocrinol Metab 93:1789–1795CrossRefPubMed

17.

Stern A, Laughlin GA, Bergstrom J et al (2007) The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappa B legend with bone mineral density in older adults: the Rancho Bernardo study. Eur J Endocrinol 156:555–562CrossRefPubMed

18.

Rogers A, Saleh G, Hannon RA et al (2002) Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. Clin Endocrinol Metab 87:4470–4475CrossRef

19.

Khosla S, Arrighi HM, Melton LJ 3rd et al (2002) Correlates of osteoprotegerin levels in women and men. Osteoporos Int 13:394–399CrossRefPubMed

20.

Ogawa S, Urano T, Hosoi T et al (1999) Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPAR gamma expression in osteoblasts. Biochem Biophys Res Commun 260:122–126CrossRefPubMed

21.

Iki M, Kagamimori S, Kagawa Y et al (2001) Bone mineral density of the spine, hip and distal forearm in representative samples of the Japanese female population: Japanese Population-Based Osteoporosis (JPOS) Study. Osteoporos Int 12:529–537CrossRefPubMed

22.

Iki M, Morita A, Ikeda Y et al (2006) Biochemical markers of bone turnover predict bone loss in perimenopausal women but not in postmenopausal women-the Japanese Population-based Osteoporosis (JPOS) Cohort Study. Osteoporos Int 17:1086–1095CrossRefPubMed

23.

WHO (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO technical report series 843

24.

Sato Y, Tamaki J, Kitayama F et al (2005) Development of a food-frequency questionnaire to measure the dietary calcium intake of adult Japanese women. Tohoku J Exp Med 207:217–222CrossRefPubMed

25.

Rizzoli R, Bonjour JP, Ferrari SL (2001) Osteoporosis, genetics and hormones. J Mol Endocrinol 26:79–94CrossRefPubMed

26.

Gajewska J, Ambroszkiewicz J, Laskowska-Klita T (2006) Osteoprotegerin and C-peptide of type 1 collagen in Polish healthy children and adolescents. Adv Med Sci 51:269–272PubMed

27.

Rouster-Stevens KA, Langman CB, Price HE et al (2007) RANKL: osteoprotogerin ratio and bone mineral density in children with untreated juvenile dermatomyositis. Arthritis Rheum 56:977–983CrossRefPubMed

28.

Hofbauer LC, Khosla S, Dunstan CR et al (2000) The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15:2–12CrossRefPubMed

29.

Henry YM, Fatayerji D, Eastell R (2004) Attainment of peak bone mass at the lumbar spine, femoral neck and radius in men and women: relative contributions of bone size and volumetric bone mineral density. Osteoporos Int 15:263–273CrossRefPubMed

Title: Peroxisome proliferator-activated receptor gamma polymorphism is related to peak bone mass: the JPOS study
Authors: J. Tamaki
M. Iki
A. Morita
Y. Ikeda
Y. Sato
E. Kajita
S. Kagamimori
Y. Kagawa
H. Yoneshima
Publication date: 01-02-2010
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 2/2010
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-009-0965-3

At a glance: The STEP trials

Springer Medicine

Peroxisome proliferator-activated receptor gamma polymorphism is related to peak bone mass: the JPOS study

Abstract

Summary

Introduction

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2010

Association between circulating osteoprogenitor cell numbers and bone mineral density in postmenopausal osteoporosis

Direct-to-participant feedback and awareness of bone mineral density testing results in a population-based sample of mid-aged Canadians

Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus

Martial arts fall training to prevent hip fractures in the elderly

Urinary levels of pentosidine and the risk of fracture in postmenopausal women: the OFELY study

A multicenter survey on profile of care for hip fracture: predictors of mortality and disability